Evidence map›Paper›PMID 25343186›Full record

ReviewJournal of neurosurgery2015

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neurosurgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 314 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
314citing papers in PubMed, 8 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

314 citing papers in PubMed, 8 syntheses or guidelines pooled it, 691 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

254 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Leland RogersGammaWest Cancer Services, Radiation Oncology, Salt Lake City, Utah;
Igor Barani
Marc Chamberlain
Thomas J Kaley
Michael McDermott
Jeffrey Raizer
David Schiff
Damien C Weber
Patrick Y Wen
Michael A Vogelbaum
University of California, San Francisco · USCancer Services · USCenter for Neuro-Oncology · USCleveland Clinic · USFred Hutch Cancer Center · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USUniversity Hospital of Geneva · CHUniversity of Virginia · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Evolving interest in meningioma, the most common primary brain tumor, has refined contemporary management of these tumors. Problematic, however, is the paucity of prospective clinical trials that provide an evidence-based algorithm for managing meningioma. This review summarizes the published literature regarding the treatment of newly diagnosed and recurrent meningioma, with an emphasis on outcomes stratified by WHO tumor grade. Specifically, this review focuses on patient outcomes following treatment (either adjuvant or at recurrence) with surgery or radiation therapy inclusive of radiosurgery and fractionated radiation therapy. Phase II trials for patients with meningioma have recently completed accrual within the Radiation Therapy Oncology Group and the European Organisation for Research and Treatment of Cancer consortia, and Phase III studies are being developed. However, at present, there are no completed prospective, randomized trials assessing the role of either surgery or radiation therapy. Successful completion of future studies will require a multidisciplinary effort, dissemination of the current knowledge base, improved implementation of WHO grading criteria, standardization of response criteria and other outcome end points, and concerted efforts to address weaknesses in present treatment paradigms, particularly for patients with progressive or recurrent low-grade meningioma or with high-grade meningioma. In parallel efforts, Response Assessment in Neuro-Oncology (RANO) subcommittees are developing a paper on systemic therapies for meningioma and a separate article proposing standardized end point and response criteria for meningioma.

Indexed as

Brain NeoplasmsCombined Modality TherapyDisease-Free SurvivalHumansMeningiomaTreatment OutcomeCGE = cobalt gray equivalentEBRT = external beam radiation therapyEORTC = European Organisation for Research and Treatment of CancerGTR = gross-total resectionMEN1 = multiple endocrine neoplasia Type 1meningiomaNF2 = neurofibromatosis Type 2oncologyoutcomesPFS = progression-free survivalradiotherapyRANO = Response Assessment in Neuro-OncologyRTOG = Radiation Therapy Oncology GroupSRS = stereotactic radiosurgerySTR = subtotal resectionsurgery

Identifiers

PMID25343186
PMCPMC5062955
OpenAlexW2159923399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.